Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
715 (USA) · Dr. Moreau
consented 2014-02-11
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate APPLICATION SITE REACTION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-21 (study day 70.0); relationship: PROBABLE
mild
assessed
Mild NAUSEA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-03-14 (study day 32.0); relationship: REMOTE
mild
assessed
Mild NAUSEA — outcome: RECOVERED/RESOLVED; onset 2014-03-14 (study day 32.0); relationship: REMOTE
mild
assessed
Mild SINUS BRADYCARDIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-22 (study day 71.0); relationship: NONE
Data queries
No data queries.